Pls. find enclosed herewith Disclosure regarding completion of US FDA Inspection at Company''s wholly owned subsidiary company site without any observation.

12th September, 2026 To, To, The General Manager The Manager, Department of Corporate Services Listing Department, BSE Ltd. National Stock Exchange of India Ltd. Phiroze Jeejeebhoy Towers, “Exchange Plaza”, C-1, Block G, Dalal Street, Bandra-Kurla Complex, Mumbai – 400 001. Bandra (E), Mumbai – 400 051. Ref.: Scrip Code No. : 540701 (Equity) Ref. : (i) Symbol – DCAL : 975834, 976560, 977467, 977859 and (ii) Series – EQ 978062 (Debt) SUB.: Disclosure pursuant to Regulations 30 and 51 of SEBI (LODR) Regulations, 2015: The Company’s wholly owned subsidiary, CARBOGEN AMCIS AG successfully completed US FDA Inspection at its manufacturing site located at Vionnaz, Switzerland without any observations. Dear Sir, With reference to the captioned subject, we would like to inform that yesterday the Company’s wholly owned subsidiary, CARBOGEN AMCIS AG’s manufacturing site located at Vionnaz, Switzerland, has successfully completed its first U.S. Food and Drug Administration (FDA) inspection without any Form 483. This successful inspection reflects the strong focus on quality parameters across the Company and its subsidiaries. The Company’s sites worldwide remain approved by major regulatory agencies. Kindly take this on your record & oblige. Thanking you. Yours faithfully, For, Dishman Carbogen Amcis Limited Shrima Dave Company Secretary